Blair McNamara, MD
Cards
About
Research
Publications
2026
A Phase II Evaluation of the Efficacy and Safety of Sacituzumab Govitecan in Patients with Recurrent Uterine Cancer.
Santin A, Roque D, Siegel E, Ettorre V, Greenman M, McNamara B, Papatla K, Kailasam A, Buza N, Clark M, Hui P, Dottino P, Ratner E, Bellone S. A Phase II Evaluation of the Efficacy and Safety of Sacituzumab Govitecan in Patients with Recurrent Uterine Cancer. Clinical Cancer Research 2026, of1-of10. PMID: 42132892, DOI: 10.1158/1078-0432.ccr-26-0144.Peer-Reviewed Original ResearchThis study investigates sacituzumab govitecan, a Trop-2–targeted drug, showing 28% response in recurrent endometrial cancer and manageable safety in heavily pretreated patients.Real World Outcomes of Pembrolizumab and Reduced-Dose Lenvatinib in Recurrent Endometrial Cancer by Platinum and p53 Status
Dzienny A, Abozenah Y, Griffith J, Sohail S, Pan Y, Vlamis C, Yamartino K, Leclair J, Israel G, Greenman M, McNamara B, Azodi M, Ratner E, Santin A, Dottino P, Papatla K, Kailasam A, Hui P, Buza N, Altwerger G. Real World Outcomes of Pembrolizumab and Reduced-Dose Lenvatinib in Recurrent Endometrial Cancer by Platinum and p53 Status. Gynecologic Oncology Reports 2026, 65: 102084. PMID: 42095053, PMCID: PMC13139971, DOI: 10.1016/j.gore.2026.102084.Peer-Reviewed Original ResearchExperiences of OBGYN Administrative Chief Residents
Ransohoff A, Conageski C, Stonehocker J, Oberman E, McNamara B, Whetstone S. Experiences of OBGYN Administrative Chief Residents. Journal Of Surgical Education 2026, 83: 103935. PMID: 41916162, DOI: 10.1016/j.jsurg.2026.103935.Peer-Reviewed Original ResearchPatient Perceptions of a Financial Resource Handout Following Gynecologic Cancer Diagnosis: A Mixed-Methods Study of Feasibility and Patient-Reported Utility
Levine A, Liu C, Harold J, McNamara B, Andikyan V. Patient Perceptions of a Financial Resource Handout Following Gynecologic Cancer Diagnosis: A Mixed-Methods Study of Feasibility and Patient-Reported Utility. Cureus 2026, 18: e104373. PMID: 41913840, PMCID: PMC13033226, DOI: 10.7759/cureus.104373.Peer-Reviewed Original Research
2025
Association of platinum-based chemotherapy with survival in ovarian carcinosarcoma: a retrospective 2-center cohort study
Abozenah Y, Erfani H, Haunschild C, Upadhyay A, Greenman M, McNamara B, Papatla K, Clark M, Dottino P, Azodi M, Santin A, Ratner E, Litkouhi B, English D, Altwerger G. Association of platinum-based chemotherapy with survival in ovarian carcinosarcoma: a retrospective 2-center cohort study. International Journal Of Gynecological Cancer 2025, 36: 104440. PMID: 41535186, DOI: 10.1016/j.ijgc.2025.104440.Peer-Reviewed Original ResearchPreclinical Efficacy of the Estrogen Receptor Degrader Fulvestrant in Combination with RAF/MEK Clamp Avutometinib and FAK Inhibitor in a Low-Grade Serous Ovarian Cancer Animal Model with Acquired Resistance to Chemotherapy and Aromatase Inhibitor
Demirkiran C, Bellone S, Ettorre V, Mansolf M, Hartwich T, McNamara B, Greenman M, Yang-Hartwich Y, Ratner E, Santin N, Sethi N, Palmieri L, Coma S, Pachter J, Ottum S, Santin A. Preclinical Efficacy of the Estrogen Receptor Degrader Fulvestrant in Combination with RAF/MEK Clamp Avutometinib and FAK Inhibitor in a Low-Grade Serous Ovarian Cancer Animal Model with Acquired Resistance to Chemotherapy and Aromatase Inhibitor. International Journal Of Molecular Sciences 2025, 26: 8924. PMID: 41009492, PMCID: PMC12469703, DOI: 10.3390/ijms26188924.Peer-Reviewed Original ResearchAdverse events beyond the RUBY trial: reporting immunotherapy-associated myocarditis, myositis, and myasthenia gravis in a real-world endometrial cancer case
Abozenah Y, McNamara B, Greenman M, Daigle E, Mikhaiel J, DiCapua D, Kwan J, Azodi M, Altwerger G. Adverse events beyond the RUBY trial: reporting immunotherapy-associated myocarditis, myositis, and myasthenia gravis in a real-world endometrial cancer case. Gynecologic Oncology Reports 2025, 61: 101950. PMID: 41169950, PMCID: PMC12570088, DOI: 10.1016/j.gore.2025.101950.Peer-Reviewed Original ResearchEffective preclinical activity of datopotamab deruxtecan (Dato-DXd), an ADC targeting trophoblast cell-surface antigen 2 (TROP2), against primary cervical carcinoma cell lines and xenografts
Ettorre V, Demirkiran C, Bellone S, Hartwich T, Greenman M, McNamara B, Sethi N, Palmieri L, Santin A. Effective preclinical activity of datopotamab deruxtecan (Dato-DXd), an ADC targeting trophoblast cell-surface antigen 2 (TROP2), against primary cervical carcinoma cell lines and xenografts. Gynecologic Oncology 2025, 201: 195-202. PMID: 40907200, DOI: 10.1016/j.ygyno.2025.08.027.Peer-Reviewed Original ResearchPreclinical Activity of Datopotamab Deruxtecan (Dato-DXd), an Antibody–Drug Conjugate Targeting TROP2, in Poorly Differentiated Endometrial Carcinomas
Santin N, Sethi N, Bellone S, Demirkiran C, Ettorre V, Greenman M, McNamara B, Buza N, Hartwich T, Palmieri L, Lorusso D, Santin A. Preclinical Activity of Datopotamab Deruxtecan (Dato-DXd), an Antibody–Drug Conjugate Targeting TROP2, in Poorly Differentiated Endometrial Carcinomas. Cancer Research Communications 2025, 5: 1611-1620. PMID: 40862536, PMCID: PMC12423748, DOI: 10.1158/2767-9764.crc-25-0251.Peer-Reviewed Original ResearchDatopotamab deruxtecan, a novel TROP2-tareting antibody-drug conjugate with a topoisomerase I inhibitor payload, shows preclinical activity against primary and metastatic uterine and ovarian TROP2 over-expressing carcinosarcoma
Greenman M, Bellone S, Demirkiran C, Hartwich T, Ettorre V, McNamara B, Sethi N, Santin N, Palmieri L, Yang-Hartwich Y, Ratner E, Santin A. Datopotamab deruxtecan, a novel TROP2-tareting antibody-drug conjugate with a topoisomerase I inhibitor payload, shows preclinical activity against primary and metastatic uterine and ovarian TROP2 over-expressing carcinosarcoma. Gynecologic Oncology 2025, 199: 64-71. PMID: 40582040, DOI: 10.1016/j.ygyno.2025.06.017.Peer-Reviewed Original Research
Academic Achievements & Community Involvement
Clinical Care
Overview
Blair C. McNamara, MD, specializes in treating patients with gynecologic cancers, including ovarian, uterine, cervical, and vulvar cancer. She provides comprehensive care for patients facing these conditions and offers individually tailored treatments that range from surgical interventions to chemotherapy. She has a passion for providing patients evidence-based treatments, including minimally invasive surgical techniques and cutting-edge targeted chemotherapies. She focuses on a “whole person” approach to cancer care and loves getting to know patients and their families while guiding them through the many choices that come with a new cancer diagnosis.
“I was drawn to gynecologic oncology very early on. It is a rare specialty in medicine where we get to offer both surgical and systemic (i.e. chemotherapy) treatments to our patients. This enables us to form long-lasting and deep bonds with our patients. that feel so rare in modern medicine more broadly.”
“We have a saying that once a patient receives a gyn cancer diagnosis, they are our patient forever! We work closely with their primary care physicians and other care team members to ensure that if they are living with cancer, or are free of disease, all aspects of their health are being tended to. I love getting to know my patients, their families, and I really feel that witnessing their strength and resilience while helping to care for them is one of the greatest privileges.”
As an assistant professor of obstetrics, gynecology, and reproductive sciences at Yale School of Medicine, Dr. McNamara conducts research aimed at improving surgical outcomes for patients. She is also investigating novel therapeutic strategies for patients with advanced or recurrent gynecologic malignancies.
Beyond taking excellent care of patients and their families, I have always wanted to have a career in academic medicine,” she explains. In all of medicine, but especially in cancer care, research has allowed us to fundamentally change the way we treat patients with gynecologic cancer. Even over the last 10 years, patients are living longer, getting cured of cancer more, and living with fewer side effects and toxicities from their treatments. Doing my part to push the field forward feels very important. Furthermore, teaching the next generation of physicians, OBGYNs, and gynecologic oncologists is so rewarding. We all have so much to learn from each other, and I love being at Yale, where there is such a strong legacy of education.”
Dr. McNamara received her medical degree from Yale School of Medicine, and completed her residency in obstetrics and gynecology at the University of California San Francisco. She then returned to Yale to complete a fellowship in gynecologic oncology.
Clinical Specialties
Board Certifications
Obstetrics & Gynecology
- Certification Organization
- AB of Obstetrics & Gynecology
- Original Certification Date
- 2025
News & Links
Media
News
- January 06, 2026Source: Yale News
Office Hours: Getting to Know… Blair McNamara
- June 23, 2025
2025 OB/GYN Research and Graduation Day
- March 20, 2025
Smilow Cancer Hospital Gynecologic Oncology Expertise in Fairfield County
- April 15, 2024
Genetic Analysis of Rare, Often Deadly Cervical Cancer Uncovers Potential Treatments
Get In Touch
Contacts
Administrative Support
Locations
Patient Care Locations
Are You a Patient? View this doctor's clinical profile on the Yale Medicine website for information about the services we offer and making an appointment.